ACH
TSHA icon

ArrowMark Colorado Holdings’s Taysha Gene Therapies TSHA Stock Holding History

ArrowMark Colorado Holdings’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115,723
Closed -$2.35M – 361
2021
Q1 		$2.35M Sell
115,723
-12,451
-10% -$337K 0.02% 266
2020
Q4 		$3.4M Sell
128,174
-198,688
-61% -$4.28M 0.03% 245
2020
Q3 		$7.32M Buy
+326,862
New +$7.69M 0.07% 177

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

ArrowMark Colorado Holdings's TSHA Position: Q2 2021 in Review

ArrowMark Colorado Holdings sold out of Taysha Gene Therapies (TSHA) in Q2 2021, closing a stake of 115,723 shares — an estimated $2.35M sold.

ArrowMark Colorado Holdings first reported a position in TSHA in Q3 2020 and held it in 3 quarters. The position peaked at $7.32M in Q3 2020. 48 funds tracked by Wall St. Rank hold TSHA as of Q2 2021.

  • ArrowMark Colorado Holdings reported no remaining Taysha Gene Therapies position as of Q2 2021 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 115,723 Taysha Gene Therapies shares in Q2 2021, an estimated $2.35M.
  • ArrowMark Colorado Holdings first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 3 quarters.
  • ArrowMark Colorado Holdings's Taysha Gene Therapies position peaked at $7.32M in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2021.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2021, filed 16 Aug 2021.